ClinVar Miner

Submissions for variant NM_004183.4(BEST1):c.1415del (p.Leu472fs) (rs752125512)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Illumina Clinical Services Laboratory,Illumina RCV000779068 SCV000915535 likely pathogenic Vitelliform macular dystrophy type 2 2018-10-18 criteria provided, single submitter clinical testing The BEST1 c.1415delT (p.Leu472ProfsTer10) variant results in a frameshift that is predicted to result in a premature termination of the protein. The p.Leu472ProfsTer10 variant has been reported in one study in which it was identified in a homozygous state in two siblings with autosomal recessive Best disease (Bitner et al. 2011). Segregation analysis revealed that both parents, two grandmothers, and three uncles were heterozygous for the variant but were unaffected, consistent with autosomal recessive inheritance. The index case was also homozygous for four silent variants previously described as non-pathogenic. Both carrier parents were heterozygous for the same four silent variants, which were shown to be in cis with the p.Leu472ProfsTer10 variant. The p.Leu472ProfsTer10 variant was reported in a heterozygous state in one of 112 ethnically matched controls (Bitner et al. 2011) and is reported at a frequency of 0.001320 in the Ashkenazi Jewish population of the Genome Aggregation Database. Functional studies conducted in MDCK cell monolayers indicated the variant has no effect on protein localization or oligomerization compared with the wild type protein (Johnson et al. 2014). However, based on their analysis of 28 BEST1 mutants, Johnson et al. conclude that Best vitelliform macular dystrophy is not associated with oligomeric defects and that mislocalization is not sufficient to produce disease. Based on the evidence, the p.Leu472ProfsTer10 variant is classified as likely pathogenic for Best vitelliform macular dystrophy. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
Invitae RCV001380021 SCV001577947 pathogenic not provided 2020-10-25 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Leu472Profs*10) in the BEST1 gene. It is expected to result in an absent or disrupted protein product. This variant is present in population databases (rs752125512, ExAC 0.007%). This variant has been observed in individual(s) with autosomal recessive Best vitelliform macular dystrophy (PMID: 21467170). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 632163). Loss-of-function variants in BEST1 are known to be pathogenic (PMID: 21825197). For these reasons, this variant has been classified as Pathogenic.
Sharon lab,Hadassah-Hebrew University Medical Center RCV000779068 SCV001160931 pathogenic Vitelliform macular dystrophy type 2 2019-06-23 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.